Lilly Advances IL-23, Gastroenterology Ambitions With Mirikizumab In Crohn's Disease
The company reported positive Phase II results and will move its potential fourth-to-market IL-23 inhibitor into Phase III in Crohn's disease later this year. Mirikizumab – in Phase III for psoriasis and ulcerative colitis – may be the second IL-23 drug for an IBD indication.
You may also be interested in...
Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.
Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its link-up with AbbVie, essentially giving the asset to the UK major for free.
The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis, J&J's first human study of two targeted immunology drugs together.